GV, MRL Ventures Fund and WuXi Healthcare Ventures participated in a series B round that lifted the small molecule therapy developer's overall funding to $120m.

US-based small molecule drug developer LifeMine Therapeutics has secured $50m of series B funding from investors including internet and technology group Alphabet and pharmaceutical firms WuXi AppTec and Merck & Co.

Milky Way Investments co-led the round with LifeMine co-founder and chairman Rick Klausner while Foresite Capital, Arch Ventures and Blue Pool Capital also invested. WuXi AppTec, Alphabet and Merck took part through WuXi Healthcare Ventures, GV and MRL Ventures Fund respectively.

LifeMine is studying fungi with a view to developing…